Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Inclusion Criteria:

- Medical History of allergy to peanuts

- Positive peanut IgE >= 0.35 kUA/L

- Positive Skin Prick test for peanut allergen during screening for study

- Positive Oral Food Challenge to peanut during screening for study

- Willingness to comply with study schedule and procedures and avoid other allergens
during study period

Exclusion Criteria:

- History of severe or life-threatening hypersensitivity event leading to ICU
admission or intubation within 60 days of screening

- Uncontrolled asthma

- Bleeding risk or coagulation disorder(s)

- Use of anticoagulants or anti-platelets (aspirin or clopidogrel may be permitted)

- History of splenectomy

- Any significant disease that would put the safety of the patient at risk. This
includes, but is not limited to: history of cancer, significant cardiac
disease/history, hematology disorders, history of GI bleeding, active infectious
process, liver disease, renal disease, immunologic disease (stable diabetes and
thyroid disease may be permitted), alcohol or drug abuse, etc.

Other protocol-defined inclusion/exclusion criteria may apply.